Related Experiment Video
Updated: May 5, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.0K
Current evaluation of alemtuzumab in multiple sclerosis
1MS Comprehensive Care Center, Stony Brook University, Department of Neurology , Stony Brook, NY 11794-8121 , USA +1 631 444 8188 ; +1 631 444 1474 ; Patricia.Coyle@stonybrookmedicine.edu.
Expert Opinion on Biological Therapy
|December 3, 2013
Summary
Alemtuzumab offers an induction therapy for relapsing multiple sclerosis (MS) by depleting lymphocytes. While effective, its use requires careful consideration of potential autoimmune disorders and infection risks.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Alemtuzumab, a CD52-directed monoclonal antibody, is approved for B-cell chronic lymphocytic leukemia.
- It depletes lymphocytes and has shown efficacy in relapsing multiple sclerosis (MS) trials.
Purpose of the Study:
- To review alemtuzumab as a therapy for MS from a United States market perspective.
- To discuss its efficacy, adverse effects, and potential role in MS treatment.
Main Methods:
- Review of PubMed for clinical trials, publications, and international meeting presentations on alemtuzumab in MS.
- Focus on data relevant to the United States market.
Main Results:
- Alemtuzumab demonstrated excellent efficacy in suppressing clinical and neuroimaging disease activity in relapsing MS.
- Phase II and III trials showed positive results in both treatment-naïve and previously treated patients.
Conclusions:
- Alemtuzumab presents an induction strategy for highly active relapsing MS patients, including selected treatment-naïve individuals.
- Its use will likely be limited to specialized centers with long-term monitoring for adverse effects like autoimmune disorders and infections.
